Association between a Specific Apolipoprotein B Mutation and Familial Defective Apolipoprotein B-100
Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extens...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 86; no. 2; pp. 587 - 591 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
National Academy of Sciences of the United States of America
01.01.1989
National Acad Sciences |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG → CAG), a CG mutational ``hot spot,'' defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia. |
---|---|
AbstractList | Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG---CAG), a CG mutational "hot spot," defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia. Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. It appears that the mutation in the codon for amino acid 3500 (CGG arrow right CAG), a CG mutational "hot spot," defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia. Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG → CAG), a CG mutational ``hot spot,'' defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia. Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG {yields} CAG), a CG mutational hot spot, defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia. Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG---CAG), a CG mutational "hot spot," defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia.Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density lipoproteins that bind defectively to the apoB,E(LDL) receptor. The disorder appears to result from a mutation in the gene for apoB-100. Extensive sequence analysis of the two alleles of one subject heterozygous for the disorder has revealed a previously unreported mutation in the codon for amino acid 3500 that results in the substitution of glutamine for arginine. This same mutant allele occurs in six other, unrelated subjects and in eight affected relatives in two of these families. A partial haplotype of this mutant apoB-100 allele was constructed by sequence analysis and restriction enzyme digestion at positions where variations in the apoB-100 are known to occur. This haplotype is the same in three probands and four affected members of one family and lacks a polymorphic Xba I site whose presence has been correlated with high cholesterol levels. Thus, it appears that the mutation in the codon for amino acid 3500 (CGG---CAG), a CG mutational "hot spot," defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia. |
Author | Vega, Gloria L. Soria, Luis F. McCarthy, Brian J. Howard R. G. Clarke Ludwig, Erwin H. Grundy, Scott M. |
AuthorAffiliation | Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140-0608 |
AuthorAffiliation_xml | – name: Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140-0608 |
Author_xml | – sequence: 1 givenname: Luis F. surname: Soria fullname: Soria, Luis F. – sequence: 2 givenname: Erwin H. surname: Ludwig fullname: Ludwig, Erwin H. – sequence: 3 fullname: Howard R. G. Clarke – sequence: 4 givenname: Gloria L. surname: Vega fullname: Vega, Gloria L. – sequence: 5 givenname: Scott M. surname: Grundy fullname: Grundy, Scott M. – sequence: 6 givenname: Brian J. surname: McCarthy fullname: McCarthy, Brian J. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6868848$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/2563166$$D View this record in MEDLINE/PubMed https://www.osti.gov/biblio/7018777$$D View this record in Osti.gov |
BookMark | eNqFks1v1DAQxS1UVLYLRy4IpAgBtyz-iD9y4LC0FJCKOABny3Fs6sprp7G3wH-Pt0lXBQScLPn93swbzRyBgxCDAeAhgisEOXk5BJVWgq3wigp-BywQbFHNmhYegAWEmNeiwc09cJTSBYSwpQIegkNMGUGMLUC_Tilqp7KLoepM_mZMqFT1aTDaWaer9RC9G-IwxmxcqF5XH7Z5glXoq1O1cd4pX50Ya3R2V-YPQ40gvA_uWuWTeTC_S_Dl9M3n43f12ce374_XZ7VmsMk1Q521kBBjO2I71uqeUq16iBhEnCBNqGK46bvWKN4IZQmhENO-pZ2g2HY9WYJXU91h221Mr03Io_JyGN1GjT9kVE7-qgR3Lr_GK4kFo6XFEjyd_DFlJ5N22ehzHUMos0kOkeB8B72Ym4zxcmtSlhuXtPFeBRO3SXIhGo5J-18QUc7LflgBn9yOvc87L6noz2ZdJa28HVXQLu0xJlhpKQpGJkyPMaXRWFkGuN5VmdV5iaDcHYzcHYwUTGJZDqa46t9cN3X_xj-ew-y-b9hb8vN_yNJuvc_mey7co4m7SDmOe5AQxCH5CaK447Q |
CODEN | PNASA6 |
CitedBy_id | crossref_primary_10_1111_j_1432_1033_1995_tb20532_x crossref_primary_10_1126_scitranslmed_aag2367 crossref_primary_10_1080_07853890802010709 crossref_primary_10_1006_mcpr_2000_0318 crossref_primary_10_1111_j_1365_2362_1994_tb02057_x crossref_primary_10_1111_j_1399_0004_1992_tb03244_x crossref_primary_10_1210_clinem_dgae784 crossref_primary_10_1161_01_ATV_17_2_348 crossref_primary_10_1016_S0211_3449_04_70166_6 crossref_primary_10_1093_clinchem_43_6_916 crossref_primary_10_1007_BF00215683 crossref_primary_10_1016_S0021_9150_99_00106_9 crossref_primary_10_1016_S0022_2275_20_43168_2 crossref_primary_10_1177_000456329202900602 crossref_primary_10_1016_S0021_9150_02_00190_9 crossref_primary_10_1016_j_atherosclerosis_2011_12_021 crossref_primary_10_1016_j_ajhg_2012_08_032 crossref_primary_10_1016_j_jacl_2019_10_007 crossref_primary_10_1016_S0021_9150_96_05967_9 crossref_primary_10_1016_S0025_7753_01_71750_2 crossref_primary_10_2217_clp_15_29 crossref_primary_10_12688_f1000research_12938_2 crossref_primary_10_1007_BF02904710 crossref_primary_10_1515_cclm_1991_29_6_395 crossref_primary_10_1093_clinchem_48_4_657 crossref_primary_10_1016_S0021_9258_18_35646_1 crossref_primary_10_12688_f1000research_12938_1 crossref_primary_10_1161_01_ATV_17_4_741 crossref_primary_10_1177_000456329603300508 crossref_primary_10_1016_S0022_2275_20_42783_X crossref_primary_10_1194_jlr_M400396_JLR200 crossref_primary_10_1038_nrcardio_2011_6 crossref_primary_10_1007_s12041_007_0020_0 crossref_primary_10_1038_sj_ejhg_5200720 crossref_primary_10_1016_j_atherosclerosis_2011_07_106 crossref_primary_10_1146_annurev_genom_083117_021136 crossref_primary_10_1038_nrendo_2010_50 crossref_primary_10_1111_j_1399_0004_1996_tb04333_x crossref_primary_10_1016_S0021_9258_19_38766_6 crossref_primary_10_1016_S0531_5131_03_00134_1 crossref_primary_10_1002_humu_1380110173 crossref_primary_10_1002__SICI_1098_1004_1996_7_1_70__AID_HUMU12_3_0_CO_2_P crossref_primary_10_1016_j_mgene_2014_07_006 crossref_primary_10_1016_j_atherosclerosis_2021_02_022 crossref_primary_10_1016_j_jacl_2017_09_003 crossref_primary_10_4158_EP_2_1_37 crossref_primary_10_1016_j_jacl_2017_09_001 crossref_primary_10_1016_j_rec_2020_06_003 crossref_primary_10_1016_S0021_9150_99_00470_0 crossref_primary_10_1016_j_atherosclerosis_2012_05_014 crossref_primary_10_1007_s11886_021_01540_0 crossref_primary_10_1016_S0022_2275_20_37419_8 crossref_primary_10_1006_mcpr_2001_0378 crossref_primary_10_1002_ejlt_200800196 crossref_primary_10_1016_S0022_2275_20_39700_5 crossref_primary_10_1016_S0022_2275_20_41098_3 crossref_primary_10_3109_10408363_2011_565585 crossref_primary_10_1146_annurev_med_042921_112629 crossref_primary_10_2217_clp_09_24 crossref_primary_10_1016_S0022_2275_20_37290_4 crossref_primary_10_1038_ejhg_2015_100 crossref_primary_10_1016_S0021_9150_96_06029_7 crossref_primary_10_1016_S0021_9150_00_00648_1 crossref_primary_10_1161_CIRCRESAHA_114_304801 crossref_primary_10_1093_clinchem_45_7_1094 crossref_primary_10_1016_S1575_0922_05_71016_0 crossref_primary_10_1258_smj_2012_012020 crossref_primary_10_2174_0929867330666230202111849 crossref_primary_10_1006_mgme_1997_2614 crossref_primary_10_1016_j_atherosclerosis_2009_01_004 crossref_primary_10_1016_j_atherosclerosis_2020_02_004 crossref_primary_10_1161_01_ATV_19_3_802 crossref_primary_10_1016_S0300_8932_03_76955_3 crossref_primary_10_1002_gepi_1370120406 crossref_primary_10_3109_07853899009147231 crossref_primary_10_1016_S0022_2275_20_40092_6 crossref_primary_10_1016_j_cell_2019_02_015 crossref_primary_10_3390_nu14071503 crossref_primary_10_1016_S0022_2275_20_33372_1 crossref_primary_10_18311_ajprhc_2018_20031 crossref_primary_10_18087_cardio_2018_11_10195 crossref_primary_10_1146_annurev_genom_082509_141637 crossref_primary_10_1161_CIRCGENETICS_116_001545 crossref_primary_10_3109_07853899009147911 crossref_primary_10_1371_journal_pgen_1008605 crossref_primary_10_1177_0004563219864379 crossref_primary_10_1007_s11427_019_1563_3 crossref_primary_10_1515_CCLM_2003_041 crossref_primary_10_1016_j_atherosclerosis_2004_07_028 crossref_primary_10_1016_S0022_2275_20_42761_0 crossref_primary_10_1046_j_1468_1331_1999_660691_x crossref_primary_10_1161_CIRCRESAHA_115_306398 crossref_primary_10_1161_circ_106_25_3373 crossref_primary_10_3109_10408363_2011_646942 crossref_primary_10_1172_JCI200318925 crossref_primary_10_1002_humu_1380040308 crossref_primary_10_1101_gr_9_10_936 crossref_primary_10_1016_j_artere_2021_02_002 crossref_primary_10_1016_S0022_2275_20_40088_4 crossref_primary_10_1016_S0009_8981_00_00367_3 crossref_primary_10_1016_S0021_9150_01_00679_7 crossref_primary_10_1016_S0031_3955_16_37021_3 crossref_primary_10_1016_S0021_9258_18_49900_0 crossref_primary_10_1093_eurjpc_zwad018 crossref_primary_10_1111_j_1365_2982_2012_01998_x crossref_primary_10_1016_j_medcli_2009_03_007 crossref_primary_10_1161_ATVBAHA_117_309326 crossref_primary_10_1016_j_atherosclerosis_2003_11_012 crossref_primary_10_1111_j_1399_0004_1993_tb03890_x crossref_primary_10_1016_j_cmet_2020_10_020 crossref_primary_10_1016_j_bbalip_2006_03_012 crossref_primary_10_1056_NEJM198906153202407 crossref_primary_10_1007_s11936_000_0010_5 crossref_primary_10_1016_j_atherosclerosis_2011_01_023 crossref_primary_10_1016_S0022_2275_20_41410_5 crossref_primary_10_1016_S0021_9150_99_00481_5 crossref_primary_10_2478_bjmg_2021_0009 crossref_primary_10_1006_geno_1997_4898 crossref_primary_10_1111_j_1749_6632_2002_tb04312_x crossref_primary_10_1515_CCLM_2000_096 crossref_primary_10_1006_mcpr_1998_0164 crossref_primary_10_1161_01_ATV_15_8_1025 crossref_primary_10_1002__SICI_1098_1004_1997_10_2_160__AID_HUMU8_3_0_CO_2_O crossref_primary_10_1016_j_jacl_2015_11_013 crossref_primary_10_1194_jlr_R017855 crossref_primary_10_1016_j_jacl_2016_01_009 crossref_primary_10_1586_14779072_1_1_107 crossref_primary_10_1111_j_1365_2362_1995_tb01709_x crossref_primary_10_1007_BF03216280 crossref_primary_10_1016_j_atherosclerosis_2016_04_011 crossref_primary_10_1136_jmedgenet_2018_105713 crossref_primary_10_1111_j_1365_2796_1992_tb00498_x crossref_primary_10_3109_00365519509089616 crossref_primary_10_1517_14796678_1_1_17 crossref_primary_10_1016_j_atherosclerosis_2003_12_021 crossref_primary_10_1016_j_atherosclerosis_2014_11_009 crossref_primary_10_1016_j_ejim_2011_01_003 crossref_primary_10_1007_BF01649457 crossref_primary_10_1007_s11883_999_0006_x crossref_primary_10_1016_0021_9150_96_05912_6 crossref_primary_10_1161_01_ATV_15_7_963 crossref_primary_10_1016_S0022_2275_20_42834_2 crossref_primary_10_1002_jcla_1037 crossref_primary_10_1016_j_bios_2015_05_014 crossref_primary_10_1038_ejhg_2010_94 crossref_primary_10_1002__SICI_1096_8628_19980413_76_5_379__AID_AJMG3_3_0_CO_2_I crossref_primary_10_1007_s11033_006_9041_7 crossref_primary_10_1016_S1058_9813_03_00049_3 crossref_primary_10_3389_fgene_2020_572045 crossref_primary_10_1515_cclm_1992_30_11_729 crossref_primary_10_1016_S0140_6736_89_92778_5 crossref_primary_10_1016_j_atherosclerosis_2012_07_030 crossref_primary_10_1097_PAT_0b013e32834efa07 crossref_primary_10_1111_j_1399_0004_2007_00915_x crossref_primary_10_1002_gepi_1370070304 crossref_primary_10_1016_j_ajhg_2023_09_003 crossref_primary_10_1016_S0021_9150_96_05990_4 crossref_primary_10_1016_S0021_9258_19_40266_4 crossref_primary_10_1007_BF00422946 crossref_primary_10_1016_S0022_2275_20_42252_7 crossref_primary_10_1007_BF00215674 crossref_primary_10_1016_j_cell_2012_03_001 crossref_primary_10_1016_j_cca_2008_07_025 crossref_primary_10_36660_abc_20210788 crossref_primary_10_1161_01_ATV_18_11_1780 crossref_primary_10_1016_j_atherosclerosis_2008_10_007 crossref_primary_10_1002__SICI_1098_1004_1996_8_2_168__AID_HUMU9_3_0_CO_2_7 crossref_primary_10_1161_HCG_0000000000000020 crossref_primary_10_1177_019262339001804a12 crossref_primary_10_1186_1471_2350_11_115 crossref_primary_10_1007_s12016_017_8611_x crossref_primary_10_1038_ng0595_28 crossref_primary_10_1074_jbc_M008890200 crossref_primary_10_1161_01_ATV_17_5_826 crossref_primary_10_1093_clinchem_46_2_224 crossref_primary_10_1111_j_1749_6632_1990_tb42274_x crossref_primary_10_1016_j_arteri_2020_08_003 crossref_primary_10_1007_s11883_021_00950_3 crossref_primary_10_1161_01_ATV_20_10_e76 crossref_primary_10_1177_153537020422900509 crossref_primary_10_1016_S0022_2275_20_35728_X crossref_primary_10_1111_j_1365_2796_1992_tb00606_x crossref_primary_10_1016_j_cca_2005_09_027 crossref_primary_10_1016_S0022_2275_20_42605_7 crossref_primary_10_1007_s10038_003_0010_x crossref_primary_10_1074_jbc_M413877200 crossref_primary_10_1016_S0021_9258_19_47176_7 crossref_primary_10_1093_hmg_ddq352 crossref_primary_10_1038_s41586_024_08223_0 crossref_primary_10_1111_j_1365_3083_2012_02734_x crossref_primary_10_1111_j_1365_2362_1991_tb01386_x crossref_primary_10_1111_j_1749_6632_1990_tb42308_x crossref_primary_10_1016_S0022_2275_20_41997_2 crossref_primary_10_1016_j_clinbiochem_2007_12_018 crossref_primary_10_1161_01_ATV_15_10_1719 crossref_primary_10_1016_j_jacl_2025_02_006 crossref_primary_10_1016_j_jacl_2016_03_043 crossref_primary_10_1515_cclm_2013_0358 crossref_primary_10_1007_BF01409399 crossref_primary_10_1161_CIRCRESAHA_120_315928 crossref_primary_10_1186_s12881_015_0230_x crossref_primary_10_1016_0140_6736_91_90920_K crossref_primary_10_3390_jcm13185615 crossref_primary_10_7554_eLife_74970 crossref_primary_10_1038_s41467_022_33510_7 crossref_primary_10_1093_clinchem_43_9_1630 crossref_primary_10_1093_cvr_cvz032 crossref_primary_10_1111_j_1365_2362_2004_01351_x crossref_primary_10_1016_j_jacl_2016_09_009 crossref_primary_10_1111_j_1365_2362_2006_01735_x crossref_primary_10_1111_cge_14453 crossref_primary_10_1016_S0022_2275_20_37702_6 crossref_primary_10_1016_S0021_9258_18_43815_X crossref_primary_10_1111_j_1365_2362_1995_tb01975_x crossref_primary_10_1161_CIRCGENETICS_113_000152 crossref_primary_10_1038_nrg_2016_160 crossref_primary_10_1080_10408360500295113 crossref_primary_10_1016_j_bbadis_2014_04_028 crossref_primary_10_1016_j_gene_2012_01_092 crossref_primary_10_1016_S0021_9150_99_00282_8 crossref_primary_10_1093_bmb_lds009 crossref_primary_10_1007_BF01644767 crossref_primary_10_1007_s12291_011_0113_7 crossref_primary_10_1016_S1016_8478_23_13082_2 crossref_primary_10_1373_clinchem_2004_038026 crossref_primary_10_5551_jat_11_131 crossref_primary_10_5858_1999_123_1219_AOOGFI crossref_primary_10_1016_j_amjcard_2010_01_356 crossref_primary_10_1016_S0022_2275_20_32424_X crossref_primary_10_3109_07853899209147821 crossref_primary_10_1093_eurheartj_ehs010 crossref_primary_10_1016_S1383_5742_98_00017_9 crossref_primary_10_1038_nature13917 crossref_primary_10_1073_pnas_1100992108 crossref_primary_10_1038_sj_ejhg_5201079 crossref_primary_10_2217_clp_10_63 crossref_primary_10_1093_clinchem_47_3_438 crossref_primary_10_1016_j_tcm_2009_05_001 crossref_primary_10_1002_mgg3_17 crossref_primary_10_1046_j_1365_2362_2001_00915_x crossref_primary_10_1111_j_1399_0004_1991_tb03024_x crossref_primary_10_1186_1743_7075_8_23 crossref_primary_10_1016_S0002_9149_98_00849_2 crossref_primary_10_1016_S0021_9150_97_00174_3 crossref_primary_10_1016_S0021_9258_18_49988_7 crossref_primary_10_1161_01_ATV_15_12_2176 crossref_primary_10_1016_S0021_9150_01_00762_6 crossref_primary_10_1056_NEJM199805283382203 crossref_primary_10_3109_07853899209147837 crossref_primary_10_1161_CIRCULATIONAHA_106_661751 crossref_primary_10_1371_journal_pone_0016721 crossref_primary_10_1194_jlr_P023697 crossref_primary_10_1007_BF00577757 crossref_primary_10_1111_j_1399_0004_1993_tb03807_x crossref_primary_10_1194_jlr_P043182 crossref_primary_10_1007_s11883_008_0030_2 crossref_primary_10_1111_j_1399_0004_1993_tb03821_x crossref_primary_10_1016_S0095_5108_18_30551_7 crossref_primary_10_1093_clinchem_44_8_1659 crossref_primary_10_1016_S0022_2275_20_32560_8 crossref_primary_10_1038_s10038_017_0347_1 crossref_primary_10_1016_S0022_2275_20_39976_4 crossref_primary_10_1007_s13258_015_0292_3 crossref_primary_10_1016_j_recesp_2020_05_034 crossref_primary_10_1002_mgg3_203 crossref_primary_10_5551_jat_27227 crossref_primary_10_3390_life12060865 crossref_primary_10_1515_CCLM_1998_106 crossref_primary_10_1016_j_abb_2007_11_009 crossref_primary_10_1016_S0022_2275_20_39683_8 crossref_primary_10_1016_j_gene_2014_09_020 crossref_primary_10_1016_S0022_2275_20_41171_X crossref_primary_10_1038_s41598_019_48402_y crossref_primary_10_1016_S0021_9258_19_30066_3 crossref_primary_10_1155_2022_7714034 crossref_primary_10_1007_BF00145346 crossref_primary_10_1002_elps_11501401164 crossref_primary_10_1016_S0022_2275_20_41629_3 crossref_primary_10_1111_j_1399_0004_1998_tb02591_x crossref_primary_10_1016_S0211_3449_08_73234_X crossref_primary_10_1016_S0022_2275_20_42634_3 crossref_primary_10_1016_S0022_2275_20_40763_1 crossref_primary_10_1016_j_atherosclerosis_2011_02_006 crossref_primary_10_1038_ncpcardio0836 crossref_primary_10_1016_S0009_8981_02_00106_7 crossref_primary_10_1016_S0021_9150_01_00439_7 crossref_primary_10_1023_A_1026704517598 crossref_primary_10_1146_annurev_med_080819_044918 crossref_primary_10_1038_346366a0 crossref_primary_10_1111_j_1526_0968_2004_00143_x crossref_primary_10_1101_gr_092841_109 crossref_primary_10_1016_j_pharmthera_2014_07_004 crossref_primary_10_1016_S0022_2275_20_39866_7 crossref_primary_10_3389_fcvm_2021_788852 crossref_primary_10_1111_j_1399_0004_1993_tb03883_x crossref_primary_10_1002_jcla_1860090616 crossref_primary_10_1002_humu_20105 crossref_primary_10_1016_j_ymgme_2008_12_014 crossref_primary_10_1111_j_1399_0004_1998_tb03699_x crossref_primary_10_1111_j_1365_2796_1992_tb01253_x crossref_primary_10_1097_01213011_200504000_00005 crossref_primary_10_1586_14737159_7_1_45 crossref_primary_10_1038_aps_2016_134 crossref_primary_10_1210_jc_2007_0221 crossref_primary_10_1007_s00439_007_0448_6 crossref_primary_10_1016_j_atherosclerosis_2021_05_007 crossref_primary_10_1111_joim_13577 crossref_primary_10_17816_MAJ630505 crossref_primary_10_1111_joim_13330 crossref_primary_10_1016_S0022_2275_20_41985_6 crossref_primary_10_1097_CRD_0000000000000384 crossref_primary_10_1016_S0022_2275_20_35115_4 crossref_primary_10_1002_humu_1380020216 crossref_primary_10_1373_clinchem_2006_067645 crossref_primary_10_1034_j_1399_0004_1999_550507_x crossref_primary_10_1038_ejhg_2013_271 crossref_primary_10_1016_S1016_8478_23_17316_X crossref_primary_10_1046_j_1365_2362_2003_01094_x |
ContentType | Journal Article |
Copyright | 1990 INIST-CNRS |
Copyright_xml | – notice: 1990 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 8FD FR3 P64 RC3 7X8 OTOTI 5PM |
DOI | 10.1073/pnas.86.2.587 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic OSTI.GOV PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Engineering Research Database Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE Genetics Abstracts MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Sciences (General) |
EISSN | 1091-6490 |
EndPage | 591 |
ExternalDocumentID | PMC286517 7018777 2563166 6868848 10_1073_pnas_86_2_587 86_2_587 33170 |
Genre | Research Support, U.S. Gov't, P.H.S Journal Article |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: HL 38781 – fundername: NCRR NIH HHS grantid: P41RR01685 |
GroupedDBID | --- -DZ -~X .55 .GJ 0R~ 123 29P 2AX 2FS 2WC 3O- 4.4 53G 5RE 5VS 85S AACGO AAFWJ AANCE ABBHK ABOCM ABPLY ABPPZ ABTLG ABXSQ ABZEH ACGOD ACHIC ACIWK ACNCT ACPRK ADQXQ ADULT ADXHL AENEX AEUPB AEXZC AFFNX AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS AQVQM AS~ CS3 D0L DCCCD DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 HGD HH5 HQ3 HTVGU HYE IPSME JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST KQ8 L7B LU7 MVM N9A NEJ N~3 O9- OK1 P-O PNE PQQKQ R.V RHI RNA RNS RPM RXW SA0 SJN TN5 UKR VOH W8F WH7 WHG WOQ WOW X7M XSW Y6R ZCA ZCG ~02 ~KM - 02 08R 0R 1AW 55 AAPBV ABFLS ABPTK ADACO ADZLD AFDAS AJYGW AS ASUFR DNJUQ DOOOF DWIUU DZ F20 GJ JSODD KM OHM PQEST RHF VQA X XFK XHC ZA5 692 6TJ 79B AAYJJ AAYXX ACKIV AFHIN AFQQW BKOMP CITATION NHB TAE YBH YKV YSK IQODW CGR CUY CVF ECM EIF NPM VXZ YIF YIN 8FD FR3 P64 RC3 7X8 OTOTI 5PM |
ID | FETCH-LOGICAL-c604t-61bff033efb3fb69cd55cad01601731c35a624db9ea748af335025d95b852fbd3 |
ISSN | 0027-8424 |
IngestDate | Thu Aug 21 14:13:44 EDT 2025 Fri May 19 01:41:28 EDT 2023 Fri Jul 11 02:03:50 EDT 2025 Fri Jul 11 01:06:05 EDT 2025 Wed Feb 19 02:35:26 EST 2025 Mon Jul 21 09:13:01 EDT 2025 Tue Jul 01 01:21:56 EDT 2025 Thu Apr 24 23:00:11 EDT 2025 Wed Nov 11 00:29:38 EST 2020 Thu May 30 08:50:27 EDT 2019 Thu May 29 08:42:23 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Apolipoprotein B Human Allele Hypercholesterolemia Nucleotide sequence Family study Deficiency Lipids Metabolic diseases Mutation Haplotype Aminoacid sequence |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c604t-61bff033efb3fb69cd55cad01601731c35a624db9ea748af335025d95b852fbd3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/286517 |
PMID | 2563166 |
PQID | 15770276 |
PQPubID | 23462 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_15770276 pubmed_primary_2563166 proquest_miscellaneous_78847239 pascalfrancis_primary_6868848 osti_scitechconnect_7018777 pnas_primary_86_2_587_fulltext crossref_citationtrail_10_1073_pnas_86_2_587 jstor_primary_33170 crossref_primary_10_1073_pnas_86_2_587 pubmedcentral_primary_oai_pubmedcentral_nih_gov_286517 pnas_primary_86_2_587 |
ProviderPackageCode | RNA PNE CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 1989-01-01 |
PublicationDateYYYYMMDD | 1989-01-01 |
PublicationDate_xml | – month: 01 year: 1989 text: 1989-01-01 day: 01 |
PublicationDecade | 1980 |
PublicationPlace | Washington, DC |
PublicationPlace_xml | – name: Washington, DC – name: United States |
PublicationTitle | Proceedings of the National Academy of Sciences - PNAS |
PublicationTitleAlternate | Proc Natl Acad Sci U S A |
PublicationYear | 1989 |
Publisher | National Academy of Sciences of the United States of America National Acad Sciences |
Publisher_xml | – name: National Academy of Sciences of the United States of America – name: National Acad Sciences |
SSID | ssj0009580 |
Score | 1.8350024 |
Snippet | Familial defective apolipoprotein (apo) B-100 is a genetic disease that leads to hypercholesterolemia and to an increased serum concentration of low density... |
SourceID | pubmedcentral osti proquest pubmed pascalfrancis crossref pnas jstor |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 587 |
SubjectTerms | 550401 - Genetics- Tracer Techniques Alleles Amino Acid Sequence Amino acids APOLIPOPROTEINS Apolipoproteins B - genetics Base Sequence BASIC BIOLOGICAL SCIENCES BETA DECAY RADIOISOTOPES BETA-MINUS DECAY RADIOISOTOPES Biological and medical sciences BLOOD CHEMISTRY CHOLESTEROL Cloning, Molecular CODONS DAYS LIVING RADIOISOTOPES DISEASES Disorders of blood lipids. Hyperlipoproteinemia DNA DNA - genetics DNA BASE TRANSITIONS DNA SEQUENCING ETIOLOGY Exons GENE MUTATIONS Genetic mutation Genetic Vectors Genotype Haplotypes HEREDITARY DISEASES Humans HYDROXY COMPOUNDS Hyperlipoproteinemia Type II - genetics ISOTOPES LIGHT NUCLEI LIPIDS LIPOPROTEINS Lipoproteins, LDL - metabolism Medical sciences MEMBRANE PROTEINS Metabolic diseases Molecular Sequence Data Mutation MUTATIONS NUCLEI NUCLEIC ACIDS ODD-ODD NUCLEI Oligonucleotides ORGANIC COMPOUNDS Pedigree PHOSPHORUS 32 PHOSPHORUS ISOTOPES Polymerase chain reaction Polymorphism, Restriction Fragment Length PROTEINS RADIOISOTOPES RECEPTORS Receptors, LDL - metabolism RECOMBINANT DNA STEROIDS STEROLS STRUCTURAL CHEMICAL ANALYSIS |
Title | Association between a Specific Apolipoprotein B Mutation and Familial Defective Apolipoprotein B-100 |
URI | https://www.jstor.org/stable/33170 http://www.pnas.org/content/86/2/587.abstract https://www.ncbi.nlm.nih.gov/pubmed/2563166 https://www.proquest.com/docview/15770276 https://www.proquest.com/docview/78847239 https://www.osti.gov/biblio/7018777 https://pubmed.ncbi.nlm.nih.gov/PMC286517 |
Volume | 86 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgvPCC2NhEGRt-QAgUUnJxHOdxQxsVKmWCFvXNspNYVIJ0Wlsh8es5jh0noZ24vESRY8dRzpfjS77zHYSek5KSpGSlLxkrfAJDsi9YpiX38xwgIoiq_55_mNDRjLyfJ_P2j24dXbKWw_znzriS_7EqlIFddZTsP1jW3RQK4BzsC0ewMBz_ysadd-sIV8LTwZOaAOQJnYHhellLMSwq79z7vrHcQr1bXm9t6P3yolTG6201AO8ZdGevV260WzXcgkmzmXjWhqZYf7HyfO9q0iY6_ry8MczccUsnHm-KHwvDL2vDJFrO0OiTS_31pTRbwO9snEQhHBXL7VQ0kQMwIhITM914XyuEvegsgo0rTexAbEblxOT02nL44KF0luJKrIaMDqOha9UV1p585Jez8ZhPL-bTu-heBCuKqPbhXX1mZqKV7CNaOVa4_ZvezXvTF8NghcF8Ce5Ys2rFCj4sZTKiaLVcaLlr5fI7Abczo5k-RA_sUgSfGVztoztldYD2G-Phl1aR_NUjVHSAhi3QsMAN0HAfN_gcN0DDADTcAA07oG010EA7RLPLi-nbkW_Tc_g5Dcjap6FUKojjUslYSZrlRZIA1LRkYZjGYR4ngkakkFkpUsKEiuMEJthFlkiWREoW8RHaq5ZV-RjhXFJGlJYuFAGRBZUiUFRkQpSFljgTA_S6ees8t9r1OoXKN15zKNKY61fNGeURByMN0AtX_dqIttxW8aA2oasVw3Q6GKBjbVAOc1AtpJxrxlm-5qnOX5lCm5OenV1byihjhA3QYd1HU9z2dbqznCvL8hqgZw1SOPh4_eNOVOVys-JhkqYATHp7jRR6TqM4G6AjgyzXDSxp4pBCU9qDnLuu5eX7V6rF11pmXsesh-mTPz7VMbrffu1P0d76ZlOewEx9LU_rb-wXMhvtyA |
linkProvider | ABC ChemistRy |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+a+specific+apolipoprotein+B+mutation+and+familial+defective+apolipoprotein+B-100&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Soria%2C+L+F&rft.au=Ludwig%2C+E+H&rft.au=Clarke%2C+HRG&rft.au=Vega%2C+G+L&rft.date=1989-01-01&rft.issn=0027-8424&rft.volume=86&rft.issue=2&rft.spage=587&rft.epage=591&rft_id=info:doi/10.1073%2Fpnas.86.2.587&rft.externalDBID=NO_FULL_TEXT |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F86%2F2.cover.gif |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F86%2F2.cover.gif |